Keyphrases
Prednisone
100%
Phase 1 Study
100%
Initial Treatment
100%
Rituximab
100%
Aggressive B-cell Lymphoma
100%
Doxorubicin
100%
Cyclophosphamide
100%
Adjusted Dose
100%
Etoposide
100%
Venetoclax
100%
Day 14
37%
Recommended Phase 2 Dose
37%
Dose-limiting Toxicity
25%
Maximum Tolerated Dose
25%
Once-daily
25%
High Risk
12%
Hyperglycemia
12%
Chemoresistance
12%
Acceptable Safety
12%
Adverse Events
12%
Overall Response Rate
12%
Twice Daily
12%
Sepsis
12%
B-cell Lymphoma 2 (Bcl-2)
12%
Abdominal Pain
12%
Safety Profile
12%
Adverse Outcomes
12%
Not Otherwise Specified
12%
Treatment Duration
12%
Serious Adverse Events
12%
Complete Response
12%
Partial Response
12%
Diffuse Large B-cell Lymphoma (DLBCL)
12%
Treatment-related Mortality
12%
Thrombocytopenia
12%
Intestinal Obstruction
12%
One-cycle
12%
Cytopenia
12%
Tolerability
12%
Indolent non-Hodgkin Lymphoma
12%
Gastrointestinal Toxicity
12%
Bcl-2 Family Proteins
12%
Hypophosphataemia
12%
Hypokalemia
12%
Gene Rearrangement
12%
Genentech
12%
Double Hit
12%
Febrile Neutropenia
12%
Previously Untreated
12%
Frontline Treatment
12%
Ann Arbor Staging
12%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
12%
High-grade B-cell Lymphoma
12%
Intravenous Rituximab
12%
Primary Mediastinal Large B-cell Lymphoma
12%
Protein Overexpression
12%
Hematological Adverse Events
12%
Dose-adjusted EPOCH-R
12%
Oral Prednisone
12%
Treatment Facilities
12%
Intravenous Cyclophosphamide
12%
Colonic Perforation
12%
Medicine and Dentistry
Arm
100%
B-Cell Lymphoma
100%
Rituximab
100%
Doxorubicin
100%
Cyclophosphamide
100%
Prednisone
100%
Etoposide
100%
Vincristine
100%
Venetoclax
100%
Adverse Event
37%
Non-Hodgkin Lymphoma
25%
Oral
25%
Infection
12%
Drug Resistance
12%
Abdominal Pain
12%
Adverse Outcome
12%
Hyperglycemia
12%
Oncology
12%
Sepsis
12%
Diffuse Large B-Cell Lymphoma
12%
Treatment Duration
12%
Bowel Obstruction
12%
Thrombocytopenia
12%
Cytopenia
12%
Gastrointestinal Toxicity
12%
Hypophosphatemia
12%
Hypokalemia
12%
Febrile Neutropenia
12%
Gene Rearrangement
12%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
12%
Primary Mediastinal B-Cell Lymphoma
12%
Colon Perforation
12%
Pharmacology, Toxicology and Pharmaceutical Science
Prednisone
100%
B Cell Lymphoma
100%
Rituximab
100%
Doxorubicin
100%
Etoposide
100%
Cyclophosphamide
100%
Vincristine
100%
Venetoclax
100%
Adverse Event
37%
Maximum Tolerated Dose
25%
Nonhodgkin Lymphoma
25%
Infection
12%
Hyperglycemia
12%
Hypophosphatemia
12%
Sepsis
12%
Abdominal Pain
12%
Adverse Outcome
12%
Diffuse Large B Cell Lymphoma
12%
Thrombocytopenia
12%
Cytopenia
12%
Tolerability
12%
Drug Resistance
12%
Febrile Neutropenia
12%
Hypokalemia
12%
Gastrointestinal Toxicity
12%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
12%
Intestine Obstruction
12%
Colon Perforation
12%